Karyopharm Therapeutics Inc.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $146.1M
- Net income
- -$196.0M
- Total assets
- $108.4M
- Market cap
- $205.8M
- Operating margin
- -62.1%
- Net margin
- -134.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $146.1M
- Operating expenses
- $236.8M
- Operating income
- -$90.7M
- Income tax
- $43.0K
- Net income
- -$196.0M
- EPS (basic)
- $-17.93
- EPS (diluted)
- $-17.93
Balance sheet
- Total assets
- $108.4M
- Current assets
- $103.1M
- Total liabilities
- $401.3M
- Current liabilities
- $92.1M
- Shareholders’ equity
- -$292.9M
Cash flow
- Operating cash flow
- -$75.4M
- Investing cash flow
- $43.4M
- Financing cash flow
- $30.0M
- Net cash flow
- -$1.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $205.8M
- EPS (diluted)
- $-17.93
- Shares outstanding
- 24.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $196.0M in FY2025.
- Revenue grew 35% from FY2020 to FY2025.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Karyopharm Therapeutics Inc..
Write a review
News about Karyopharm Therapeutics Inc.
News & sentiment via Polygon.io
